Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06543043 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06543043 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 30 participants.
The verdict
NCT06543043, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single-center, open-label, parallel group study designed to investigate the effect of CYP3A induction and inhibition following multiple doses of phenytoin (Part A) and itraconazole (Part B), respectively, on the pharmacokinetics of sonrotoclax in healthy volunteers.
Interventions
- DRUG Itraconazole
- DRUG Phenytoin
- DRUG sonrotoclax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06543043
The ClinicalTrials.gov registry entry for NCT06543043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT06543043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06543043 about?
NCT06543043 is a clinical study titled "A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers". This is a single-center, open-label, parallel group study designed to investigate the effect of CYP3A induction and inhibition following multiple doses of phenytoin (Part A) and itraconazole (Part B), respectively, on the pharmacokinetics of sonrotoclax in healthy volunteers.
What is the current status of trial NCT06543043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-08-19. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT06543043?
The interventions under investigation include: Itraconazole (DRUG), Phenytoin (DRUG), sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT06543043?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.